Trials / Withdrawn
WithdrawnNCT04526717
Heat Shock Protein Inhibitor- MPT0B640 for COVID-19 Infection
Phase 1, Open Label, Single Arm Study to Evaluate the Safety, Tolerability and Efficacy of MPT0B640 in Patients With COVID-19 Infection
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- J Ints Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Indication : Treatment of Subject with COVID-19 infection Phase : Phase I Duration of Study : 12 day Sample size : at least 15 subjects Methodology : Classical 3+3 design Investigational Product : MPT0B640, 15, 30, 60, 80 and 100mg, oral suspension Study Objective 1. Primary Objective To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD) of MPT0B640 2. Secondary Objectives To evaluate the safety and tolerability of MPT0B640 during entire study period To assess the efficacy of MPT0B640 To characterize the 48 hours PK of MPT0B640
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MPT0B640 | Each dose of MPT0B640 will be administrated per Cohort. (15, 30, 60, 80, 100 mg of MPT0B640) |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2020-08-26
- Last updated
- 2021-06-11
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04526717. Inclusion in this directory is not an endorsement.